Elanco Animal Health Incorporated (NYSE:ELAN) Shares Purchased by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. lifted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 13.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 343,992 shares of the company's stock after acquiring an additional 39,548 shares during the quarter. Jupiter Asset Management Ltd. owned 0.07% of Elanco Animal Health worth $4,964,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. American Century Companies Inc. raised its position in shares of Elanco Animal Health by 4.1% during the 2nd quarter. American Century Companies Inc. now owns 122,096 shares of the company's stock worth $1,762,000 after purchasing an additional 4,757 shares during the last quarter. Linscomb Wealth Inc. raised its holdings in Elanco Animal Health by 6.9% in the 2nd quarter. Linscomb Wealth Inc. now owns 82,472 shares of the company's stock valued at $1,190,000 after acquiring an additional 5,325 shares during the last quarter. Headlands Technologies LLC raised its holdings in Elanco Animal Health by 2,484.4% in the 2nd quarter. Headlands Technologies LLC now owns 29,204 shares of the company's stock valued at $421,000 after acquiring an additional 28,074 shares during the last quarter. Choreo LLC acquired a new stake in Elanco Animal Health in the 2nd quarter valued at about $620,000. Finally, Private Management Group Inc. boosted its position in shares of Elanco Animal Health by 25.7% during the 2nd quarter. Private Management Group Inc. now owns 887,203 shares of the company's stock worth $12,802,000 after purchasing an additional 181,306 shares during the period. 97.48% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Michael J. Harrington acquired 3,500 shares of Elanco Animal Health stock in a transaction dated Thursday, August 22nd. The shares were acquired at an average cost of $14.85 per share, for a total transaction of $51,975.00. Following the acquisition, the director now owns 81,094 shares of the company's stock, valued at $1,204,245.90. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CEO Jeffrey N. Simmons purchased 100,000 shares of the business's stock in a transaction that occurred on Monday, August 12th. The shares were purchased at an average cost of $13.01 per share, for a total transaction of $1,301,000.00. Following the purchase, the chief executive officer now directly owns 145,000 shares of the company's stock, valued at $1,886,450. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael J. Harrington purchased 3,500 shares of the business's stock in a transaction that occurred on Thursday, August 22nd. The shares were bought at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the purchase, the director now directly owns 81,094 shares in the company, valued at $1,204,245.90. The disclosure for this purchase can be found here. Company insiders own 0.57% of the company's stock.

Elanco Animal Health Stock Up 0.6 %

ELAN stock traded up $0.08 during midday trading on Friday, hitting $14.47. The company's stock had a trading volume of 3,020,891 shares, compared to its average volume of 4,746,100. The company has a quick ratio of 1.75, a current ratio of 2.93 and a debt-to-equity ratio of 0.92. Elanco Animal Health Incorporated has a 52-week low of $8.52 and a 52-week high of $18.80. The firm has a market capitalization of $7.15 billion, a P/E ratio of -5.46, a PEG ratio of 1.44 and a beta of 1.40. The firm has a 50-day simple moving average of $13.87 and a 200-day simple moving average of $15.20.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.24 by $0.06. Elanco Animal Health had a negative net margin of 27.94% and a positive return on equity of 7.29%. The company had revenue of $1.18 billion during the quarter, compared to analysts' expectations of $1.15 billion. During the same quarter last year, the company posted $0.18 EPS. The firm's revenue was up 12.0% compared to the same quarter last year. As a group, equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analyst Upgrades and Downgrades

ELAN has been the subject of a number of research analyst reports. Piper Sandler lowered their price objective on shares of Elanco Animal Health from $19.00 to $16.00 and set a "neutral" rating for the company in a research report on Monday, July 1st. Barclays lowered their price objective on shares of Elanco Animal Health from $23.00 to $21.00 and set an "overweight" rating for the company in a research report on Friday, June 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.57.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.